

# Radiology-Pathology Conference

Shanna Matalon, PGY-3


Navin Mahadevan, PGY-1

# Case 1

- 84 year old male presenting with right groin pain/pressure
- U/A showed hematuria

# What is the appropriate next step?

- A. KUB
- B. Renal U/S
- C. CT abd/pelvis I-
- ★ D. CT Urogram



# ACR Appropriateness Criteria

**Clinical Condition:** Acute Onset Flank Pain — Suspicion of Stone Disease

**Variant 1:** Suspicion of stone disease.

Radiologic Procedure	Rating	Comments	RRL*
CT abdomen and pelvis without contrast	8	Reduced-dose techniques preferred.	⊕⊕⊕⊕
CT abdomen and pelvis without and with contrast	6	If CT without contrast does not explain pain or if without has abnormality that should be further assessed with contrast (ex. stone versus phleboliths).	⊕⊕⊕⊕
US kidneys and bladder retroperitoneal with Doppler and KUB	6	Preferred examination in pregnancy, in patients who are allergic to iodinated contrast, and if NCCT is not available.	⊕⊕
X-ray intravenous urography	4		⊕⊕⊕
MRI abdomen and pelvis without contrast (MR urography)	4		O
MRI abdomen and pelvis without and with contrast (MR urography)	4	See statement regarding contrast in text under "Anticipated Exceptions."	O
CT abdomen and pelvis with contrast	2		⊕⊕⊕⊕
X-ray abdomen and pelvis (KUB)	1	Most useful in patients with known stone disease.	⊕⊕

**Rating Scale:** 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate

\*Relative Radiation Level


# Non-contrast CT and stones

- Highest sensitivity (95-96%) and specificity (98%)
- Virtually all stones are radiopaque
- \*Pregnancy


# That's all great, but...

- 84 year old male with new stone?
- What else should we consider...?


# Renal stone protocol CT



FNA of Lung Lesion → Poorly-differentiated small cell



# Further evaluation...




113 HU



# Differential diagnosis

- Metastatic lung cancer
- Synchronous RCC
- Oncocytoma
- Fat-poor AML



In a patient with a known primary malignancy, what percentage of renal masses represent metastasis?

- A. ~20%
- ★ B. ~40%
- C. ~60%
- D. ~80%






# Pathology



PAX8



Hales colloidal iron


**ONCOCYTOMA**

# Oncocytoma

# Case 2

- 77 year old male with prostatitis and recurrent bothersome lower urinary tract symptoms

# Outside hospital work up



# ACR Appropriateness Criteria

Clinical Condition: Indeterminate Renal Mass → 20-70 HU

Variant 1: Patient with normal renal function.


Radiologic Procedure	Rating	Comments	RRL*
CT abdomen without and with contrast	9	Either CT or MRI is appropriate. Use thin-section CT.	++++
MRI abdomen without and with contrast	8	Either CT or MRI is appropriate. See statement regarding contrast in text under "Anticipated Exceptions."	O
US kidney retroperitoneal with duplex Doppler	8		O
Biopsy renal mass	5		Varies
MRI abdomen without contrast	3	This procedure can be useful to characterize simple cysts.	O
Arteriography kidney	1		***
X-ray intravenous urography	1		***
CT abdomen with contrast	1		***
CT abdomen without contrast	1		***

Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate

\*Relative  
Radiation Level



85 HU





T2


T2 FS

Pre


Post



In




Out





# Differential diagnosis

- RCC
- Oncocytoma
- Leiomyoma/sarcoma

# Pathology



# RCC, CHROMOPHOBIC



Download from  
 Dreamstime.com

1485384  
 Dreamstime.com


# Chromophobe RCC

# Case 3

- 64 year old male presenting with newly elevated creatinine

# What is the appropriate next (imaging) step?

- A. I- CT abd/pelvis
- ★ B. Renal ultrasound
- C. Renal biopsy
- D. MAG3 study



# ACR Appropriateness Criteria

Clinical Condition: Renal Failure

Variant 1: Acute kidney injury (AKI), unspecified.

Radiologic Procedure	Rating	Comments	RRL*
US kidneys and bladder	9	Assess renal size and echogenicity. Exclude bilateral obstruction in high-risk groups. Doppler may be used to assess renal perfusion.	O
Percutaneous US-guided renal biopsy	6	Especially useful in acute inflammatory conditions such as nephritis. Perform a follow-up after US examination, if needed.	O
Tc-99m MAG3 scan kidney	4	This procedure may be useful if the creatinine level is high. Perform a follow-up after US examination, if needed.	***
CT abdomen without contrast	3	Potentially helpful in trauma evaluation. Noncontrast helical CT is more sensitive than KUB for calculi. Evaluation of ureteral obstruction due to retroperitoneal diseases, masses, and tumors (hydronephrosis on US but an undetectable cause).	***

Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate


\*Relative  
Radiation Level



Q

TRV RT KID DECUB  
LOWER \_

14fps



Q

TRV RT KID DECUB  
LOWER \_

8fps

# ACR Appropriateness Criteria


Clinical Condition: Indeterminate Renal Mass

Variant 2: Patient with renal insufficiency (contraindication to intravenous contrast).

Radiologic Procedure	Rating	Comments	RRL*
US kidney retroperitoneal with duplex Doppler	8		O
MRI abdomen without contrast	7		O
Biopsy renal mass	6		Varies
CT abdomen without contrast	5	This procedure may be useful to detect fat in AMLs or attenuation value in cysts.	***
MRI abdomen without and with contrast	3	This procedure is rated higher than CT because the incidence of NSF is less than the incidence of CIN.	O
CT abdomen without and with contrast	2	This procedure is rated lower than MRI because the incidence of CIN is greater than the incidence of NSF.	****
CT abdomen with contrast	1		***
X-ray intravenous urography	1		***
Arteriography kidney	1		***

**Rating Scale:** 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate


\*Relative Radiation Level




34 HU

45 HU


T2




Pre



T2




Post





# Differential

- RCC
- Oncocytoma
- Metastasis from unknown primary
- Leiomyosarcoma


# Pathology







RCC, CLEAR CELL TYPE




# Clear cell RCC

# Case 4

- 67 year old male with prostate adenocarcinoma with incidental renal lesions detected on prostate/pelvic MR

# Large FOV axial post-contrast image



# ACR Appropriateness Criteria

Clinical Condition: Indeterminate Renal Mass

Variant 1: Patient with normal renal function.

Radiologic Procedure	Rating	Comments	RRL*
CT abdomen without and with contrast	9	Either CT or MRI is appropriate. Use thin-section CT.	++++
MRI abdomen without and with contrast	8	Either CT or MRI is appropriate. See statement regarding contrast in text under "Anticipated Exceptions."	O
US kidney retroperitoneal with duplex Doppler	8		O
Biopsy renal mass	5		Varies
MRI abdomen without contrast	3	This procedure can be useful to characterize simple cysts.	O
Arteriography kidney	1		+++
X-ray intravenous urography	1		+++
CT abdomen with contrast	1		+++
CT abdomen without contrast	1		+++


Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate


\*Relative  
Radiation Level

# Renal mass protocol




# Renal mass protocol






T2




Out




Pre



T2 FS




In



Post

If chemical shift imaging (in/out of phase) demonstrated signal drop-out, diagnosis would be:

- A. AML
- B. Clear cell RCC
- ★C. Either**
- D. Neither




# Differential

- Fat poor AML
- Papillary RCC
- Prostate metastasis
- Lymphoma
- Oncocytoma


# What is the best next step?

- ★ A. Biopsy
- B. Partial nephrectomy
- C. MRI follow-up in 1 year
- D. Nothing, we're done here



# Pathology

SPINDLE CELL NEOPLASM most  
suggestive of (SPINDLE CELL  
PREDOMINANT) ANGIOMYOLIPOMA




Fat poor (spindle predominant)

AML

# End of cases!


# What is the theme of today's Rad-Path conference?

- A. RCC
- B. Men with kidney problems
- ★C. Hyperattenuating renal lesions
- D. Brain tumors



# Hyperattenuating renal masses

- Higher attenuation than renal parenchyma (~30 HU) so basically anything 40-90 HU
- Causes? Some examples:
  - Densely packed cells
  - Diffuse microcalcifications
  - Colloid/proteinaceous
  - Hemorrhage



# Hyperattenuating Renal Masses: Etiolo- gies, Pathogenesis, and Imaging Evaluation<sup>1</sup>

*Stuart G. Silverman, MD • Koenraad J. Mortele, MD • Kemal Tuncali,  
MD • Masahiro Jinzaki, MD • Edmund S. Cibas, MD*

- Colloid/proteinaceous
- Hemorrhage

# Hyperattenuating renal lesions: Ddx

## Benign

### Nonenhancing

- “Hyperdense” cyst
- Hematoma

### Enhancing



- AML
- Oncocytoma
- Vascular anomalies
- Focal (hemorrhagic) pyelonephritis
- Tuberculosis
- Leiomyoma
- Extramedullary hematopoiesis
- Metanephric adenoma

## Malignant

- RCC (papillary, clear cell, chromophobe)
- Lymphoma
- Metastases
- Leiomyosarcoma



# Benign

# “Hyperdense” cysts




# Proteinaceous or hemorrhagic cyst

- Most common
- Small (<3 cm)
- Round
- Well-circumscribed
- Homogeneous\*
- Non-enhancing\*\*



To make a confident diagnosis on an I- exam, a hyperdense cyst must measure at least:


- A. 40 HU
- B. 70 HU
- C. 90 HU
- D. Cannot be confident



Ari I. Jonisch, MD  
Ami N. Rubinowitz, MD  
Pradeep G. Mutalik, MD  
Gary M. Israel, MD

# Can High-Attenuation Renal Cysts Be Differentiated from Renal Cell Carcinoma at Unenhanced CT?<sup>1</sup>

- Attenuation >70 HU
- Homogeneous




# Hematoma





# Hematoma

- Spontaneous, post-traumatic, tumor\*\*
- Usually perinephric (crescentric)
  - Less commonly, masslike
- Non-enhancing
- +/- perinephric stranding
- +/- peripheral calcifications






# Vascular anomalies




# Vascular anomalies

- AVM, pseudoaneurysm, aneurysm
- Thrombus can be high attenuation
- Saccular/tubular shape
- Attenuation matches nearby blood vessels
- Look for draining veins




# Focal (hemorrhagic) pyelonephritis



# Focal (hemorrhagic) pyelonephritis

- Clinical diagnosis
- Imaging often “normal”
- Wedge-shaped/rounded areas of decreased enhancement
- Loss of corticomedullary differentiation
- Associated inflammation
- Rarely, hyperattenuating (hemorrhagic)




# Tuberculosis




# Tuberculosis

- #1 extrapulmonary site
- Presentation is atypical for UTI
- Hematuria & culture-negative
- Granulomas → spread into medulla, papillae & collecting ducts
- Triad:
  - Calcifications
  - Urothelial thickening, stricture
  - Cortical scarring
  - \*\*Stage of disease



Craig, W.D., B.J. Wagner, and M.D. Travis. Radiographics, 2008.  
Merchant, S., A. Bharati, and N. Merchant. Indian J Radiol Imaging, 2013.

# Leiomyoma




# Leiomyoma

- 1.5% of benign renal tumors
- Arise from smooth muscle of renal capsule, calyces, or blood vessels
- Well-defined, round, hyperdense, homogeneously enhancing
- DDx: Leiomyosarcoma, AML
  - Need histology



# Extramedullary hematopoiesis



# Extramedullary hematopoiesis

- Due to erythropoiesis failure in bone marrow (ex: myelofibrosis)
- Most often spleen, liver, lymph nodes
- Renal involvement rare
  - Parenchymal, intrapelvic, perirenal
- Differential: RCC, urothelial carcinoma, lymphoma
  - Diagnosis of exclusion




# Oncocytoma




# Oncocytoma

- 2<sup>nd</sup> most common benign tumor
- Epithelial cells, arising from collecting ducts
- Average = size 7 cm
- Variable appearance
  - +/- central stellate scar\*
- No malignant features
- Enhancing (< renal parenchyma)




# Angiomyolipoma



StatDx: Angiomyolipoma





# Angiomyolipoma

- Macroscopic fat (-10 HU)
- 4-5% contain little to no fat
  - MR usually unhelpful
    - Fat suppression sequences
    - Chemical shift imaging (in/out of phase)
- Noncalcified\*
- Large feeding arteries
- Ddx: liposarcoma
  - Usually RP
  - No claw sign



StatDx: Angiomyolipoma


# The many faces of AML



Jinzaki, M., et al.  
Radiology, 1997.  
Silverman, S.G., et al.  
Radiographics, 2007.

StatDx: Angiomyolipoma


# Fat-poor AML



Jinzaki, M., et al. Radiology, 1997.

Silverman, S.G., et al. Radiographics, 2007.

# Fat-poor AML




Jinzaki, M., et al. Radiology, 1997.

Silverman, S.G., et al. Radiographics, 2007.



# Malignant

# Lymphoma



# Lymphoma

- NHL > HL (10:1)
- Primary only 3%
- Usually hypoattenuating
- Variable pattern
  - Solitary (10%)
  - Multiple (60%)
  - Diffuse infiltration (20%)
  - Perirenal (10%)
- Homogeneous
- Minimal enhancement



# Metastases



StatDx: Metastases and Lymphoma, Renal

# Metastases

- 54 masses in patients with a known extrarenal primary cancer and unknown renal mass
- 31 masses (57%) = RCC
- Most common primaries = lymphoma & lung
  - N=36
  - 50% were RCC
- → Biopsy indicated

# Metastases

## Percutaneous Biopsy of Renal Masses: Sensitivity and Negative Predictive Value Stratified by Clinical Setting and Size of Masses

Frank J. Rybicki<sup>1</sup>

Kirstin M. Shu<sup>1</sup>

Edmund S. Cibas<sup>2</sup>

Julia R. Fielding<sup>1,3</sup>

Eric vanSonnenberg<sup>1</sup>

Stuart G. Silverman<sup>1</sup>

na & lung

- N=36
- 50% were RCC

- → Biopsy indicated



TABLE 4

Diagnoses of 54 Renal Masses in Patients with a Known Extrarenal Primary Malignancy

Primary Malignancy	No. of Masses	Diagnosis		
		Metastasis	Renal Cell Carcinoma	Benign
Lymphoma	20	9	10	1
Lung	16	8	8	0
Breast	5	1	3	1
Ovarian	3	0	3	0
Colon	2	1	1	0
Prostate	2	0	2	0
Bladder	2	0	2	0
Tongue	1	0	1	0
Testis	1	1	0	0
Leimyosarcoma	1	0	0	1
Duodenal	1	0	1	0
Total	54	20	31	3

RCC

# The many faces of RCC



# RCC Subtypes

Subtype	%	CT features	MR features	Enhancement
Clear cell	70	Heterogeneous	T2 hyperintense +/- OOP signal dropout	Hyperenhancing
Papillary	10	Variable	T2 hypointense	Hypoenhancing
Chromophobe	5	Homogeneous	T2 hypointense	Homogeneously enhancing
Multilocular				
Xp11.2 translocation				
Collecting duct	<1			
Medullary				
Etc...				

Prasad, S.R., et al. Radiographics, 2006.

Raman, S.P., et al. AJR Am J Roentgenol, 2013.

# Approach to hyperdense lesion\*

## Findings on CT I-

Feature	Likely diagnosis
>70 HU (& homogen)	Hyperdense cyst
Focal fat	“Typical” AML
Stranding	Consider: Hematoma Pyelonephritis
Calcifications, scarring, stricture	TB

## Findings on CT I+

Feature	Likely diagnosis
Nonenhancing	Hyperdense cyst Hematoma
HU ≈ nearby vessels +/- draining veins	Vascular anomaly
Enhancing; indeterminate	MRI and/or biopsy

## Findings on MRI

Feature	Likely diagnosis
Focal fat suppression	“Typical” AML
Signal drop on OOP	Clear cell RCC (usually T2 hyper) AML (usually T2 hypo)
T2 hypointense	“Fat-poor” AML (hyperenhancing) Papillary RCC (hypoenhancing)
T2 Iso- or hyperintense	RCC +/- oncocytoma

# ...Now what?

TABLE 4. Proportion of clear cell, papillary and chromophobe RCC by tumor size

Tumor Size (cm)	No. Clear Cell (%)	No. Papillary (%)	No. Chromophobe (%)
0.0-Less than 1.0	11 (25.6)	32 (74.4)	0 (0.0)
1.0-Less than 2.0	79 (59.9)	51 (38.6)	2 (1.5)
2.0-Less than 3.0	186 (70.2)	69 (26.0)	10 (3.8)
3.0-Less than 4.0	203 (72.0)	69 (24.5)	10 (3.6)
4.0-Less than 5.0	268 (80.2)	47 (14.1)	19 (5.7)
5.0-Less than 6.0	218 (82.0)	40 (15.0)	8 (3.0)
6.0-Less than 7.0	192 (83.5)	30 (13.0)	8 (3.5)
7.0 or Greater	813 (83.0)	98 (10.0)	68 (7.0)

Percentages indicate the proportion of RCC tumors in each size category that are clear cell, papillary and chromophobe, respectively.

# ...Now what?

**TABLE 4. Proportion of clear cell, papillary and chromophobe RCC**

**TABLE 5. Proportion of low grade versus high grade tumors by RCC histological subtype and tumor size**


	No. Clear Cell (%)		No. Papillary (%)		No. Chromophobe (%)	
	Low Grade	High Grade	Low Grade	High Grade	Low Grade	High Grade
<b>Tumor size (cm):</b>						
0.0-Less than 1.0	10 (90.9)	1 (9.1)	32 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)
1.0-Less than 2.0	70 (88.6)	9 (11.4)	38 (74.5)	13 (25.5)	2 (100.0)	0 (0.0)
2.0-Less than 3.0	174 (93.6)	12 (6.5)	50 (72.5)	19 (27.5)	8 (80.0)	2 (20.0)
3.0-Less than 4.0	165 (81.3)	38 (18.7)	52 (75.4)	17 (24.6)	6 (60.0)	4 (40.0)
4.0-Less than 5.0	208 (77.6)	60 (22.4)	31 (66.0)	16 (34.0)	13 (68.4)	6 (31.6)
5.0-Less than 6.0	151 (69.3)	67 (30.7)	30 (75.0)	10 (25.0)	5 (62.5)	3 (37.5)
6.0-Less than 7.0	117 (60.9)	75 (39.1)	20 (66.7)	10 (33.3)	6 (75.0)	2 (25.0)
7.0 or Greater	308 (37.9)	505 (62.1)	55 (56.1)	43 (43.9)	51 (75.0)	17 (25.0)
<b>Totals</b>	<b>1,203</b>	<b>767</b>	<b>308</b>	<b>128</b>	<b>91</b>	<b>34</b>

Percentages indicate the proportion of RCC tumors in each size and RCC subtype that are low grade and high grade, respectively.


<b>6.0-Less than 7.0</b>	<b>192 (83.5)</b>	<b>30 (13.0)</b>	<b>8 (3.5)</b>
<b>7.0 or Greater</b>	<b>813 (83.0)</b>	<b>98 (10.0)</b>	<b>68 (7.0)</b>

Percentages indicate the proportion of RCC tumors in each size category that are clear cell, papillary and chromophobe, respectively.

# ...Guidelines



# Thank you!



# References

- Berland, L.L., et al., *Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee*. J Am Coll Radiol, 2010. **7**(10): p. 754-73.
- Bluth, E.I., et al., *Indeterminate renal masses*. American College of Radiology. ACR Appropriateness Criteria. Radiology, 2000. **215 Suppl**: p. 747-52.
- Coursey, C.A., et al., *ACR Appropriateness Criteria(R) acute onset flank pain--suspicion of stone disease*. Ultrasound Q, 2012. **28**(3): p. 227-33.
- Craig, W.D., B.J. Wagner, and M.D. Travis, *Pyelonephritis: radiologic-pathologic review*. Radiographics, 2008. **28**(1): p. 255-77; quiz 327-8.
- Frank, I., et al., *Solid renal tumors: an analysis of pathological features related to tumor size*. J Urol, 2003. **170**(6 Pt 1): p. 2217-20.
- Gupta, R., A. Seith, and B. Guglani, *Renal hilar extramedullary hematopoiesis presenting as incidental unilateral renal hilar mass in adolescent male: a case report*. Int Urol Nephrol, 2009. **41**(1): p. 19-21.
- Israel, G.M. and M.A. Bosniak, *Pitfalls in renal mass evaluation and how to avoid them*. Radiographics, 2008. **28**(5): p. 1325-38.
- Jinzaki, M., et al., *Renal angiomyolipoma: a radiological classification and update on recent developments in diagnosis and management*. Abdom Imaging, 2014. **39**(3): p. 588-604.
- Jinzaki, M., et al., *Angiomyolipoma: imaging findings in lesions with minimal fat*. Radiology, 1997. **205**(2): p. 497-502.
- Jonisch, A.I., et al., *Can high-attenuation renal cysts be differentiated from renal cell carcinoma at unenhanced CT?* Radiology, 2007. **243**(2): p. 445-50.
- Merchant, S., A. Bharati, and N. Merchant, *Tuberculosis of the genitourinary system-Urinary tract tuberculosis: Renal tuberculosis-Part II*. Indian J Radiol Imaging, 2013. **23**(1): p. 64-77.
- Prasad, S.R., et al., *Common and Uncommon Histologic Subtypes of Renal Cell Carcinoma: Imaging Spectrum with Pathologic Correlation*. Radiographics, 2006. **26**: 1795-1810.
- Raman, S.P., et al., *Chromophobe renal cell carcinoma: multiphase MDCT enhancement patterns and morphologic features*. AJR Am J Roentgenol, 2013. **201**(6): p. 1268-76.
- Remer, E.M., et al., *ACR Appropriateness Criteria on Renal Failure*. Am J Med, 2014. **127**(11): p. 1041-1048 e1.
- Rybicki, F.J., et al., *Percutaneous biopsy of renal masses: sensitivity and negative predictive value stratified by clinical setting and size of masses*. AJR Am J Roentgenol, 2003. **180**(5): p. 1281-7.
- Schuster, T.G., et al., *Papillary renal cell carcinoma containing fat without calcification mimicking angiomyolipoma on CT*. AJR Am J Roentgenol, 2004. **183**(5): p. 1402-4.
- Silverman, S.G., et al., *Hyperattenuating renal masses: etiologies, pathogenesis, and imaging evaluation*. Radiographics, 2007. **27**(4): p. 1131-43.
- Silverman, S.G., et al., *Management of the incidental renal mass*. Radiology, 2008. **249**(1): p. 16-31.